Mobile

Pediatric PK Study (POS IV and PFS)

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002807-10

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the pharmacokinetics (PK) of POS IV solution and POS Powder for Oral Suspension (PFS) administered to immunocompromised pediatric subjects (ages 2 years to 17 years)with neutropenia or expected neutropenia.

Critère d'inclusion

  • Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia

Liens